Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
PR Newswire
CARMIEL, Israel, Aug. 12, 2026
Company to host conference call and webcast today at 8:00 a.m. EDTRevenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio®Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone paymentYear-to-date, the Company achieved profitability with a net income of $22.1 millionThe Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenuePRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.
